Form 4: Sutro Biopharma CEO Jane Chung Reports Stock Option and RSU Grants
SEC Form 4 Filing
CEO Jane Chung reports the acquisition of stock options and restricted stock units (RSUs) in Sutro Biopharma, Inc.
Summary
- Jane Chung, CEO of Sutro Biopharma, Inc., filed a Form 4 disclosing changes in beneficial ownership.
- On April 4, 2025, Ms. Chung was granted stock options to purchase 620,000 shares of common stock at an exercise price of $0.55.
- These options vest monthly starting May 4, 2025, and will be fully vested by April 4, 2029, contingent upon continued service to the company.
- Ms. Chung also received 310,000 Restricted Stock Units (RSUs) on April 4, 2025.
- These RSUs vest annually beginning March 2, 2026, with full vesting by March 2, 2029, also subject to continued service.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The grant of stock options and RSUs to the CEO aligns her interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to the company's long-term success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.
Industry Context
Stock option and RSU grants are a common practice in the biopharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron also utilize stock options and RSUs to align executive incentives with shareholder value.
- The vesting schedules are typical, with monthly or annual vesting over a period of several years.
Stakeholder Impact
- Shareholders: The grants align the CEO's interests with increasing shareholder value.
- Employees: The grants may have a positive impact on employee morale as they demonstrate the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/04/2025 | Date of transaction: grant of stock options and RSUs. |
| 05/04/2025 | First vesting date for stock options (monthly vesting). |
| 03/02/2026 | First vesting date for RSUs (annual vesting). |
| 04/04/2029 | Full vesting date for stock options. |
| 03/02/2029 | Full vesting date for RSUs. |
| 04/08/2025 | Date of Form 4 filing. |
Keywords
Form 4, Sutro Biopharma, Jane Chung, Stock Options, RSUs, Beneficial Ownership, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.